- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
Détention brevets de la classe C07K 14/74
Brevets de cette classe: 1958
Historique des publications depuis 10 ans
|
77
|
90
|
113
|
173
|
225
|
228
|
278
|
241
|
203
|
132
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1155 |
526 |
| Cue Biopharma, Inc. | 187 |
95 |
| Regeneron Pharmaceuticals, Inc. | 4377 |
59 |
| CRISPR Therapeutics AG | 372 |
55 |
| University Health Network | 1056 |
29 |
| 10X Genomics, Inc. | 1263 |
23 |
| The Regents of the University of California | 20195 |
18 |
| Board of Regents, The University of Texas System | 5906 |
18 |
| Imcyse SA | 74 |
15 |
| Universite de Montreal | 344 |
15 |
| Sangamo Therapeutics, Inc. | 422 |
15 |
| Sana Biotechnology, Inc. | 161 |
15 |
| Ecole Polytechnique Federale de Lausanne (epfl) | 1560 |
14 |
| Oregon Health & Science University | 764 |
14 |
| Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 287 |
13 |
| UTi Limited Partnership | 453 |
12 |
| President and Fellows of Harvard College | 6014 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2607 |
11 |
| Immunocore Limited | 221 |
11 |
| Xyphos Biosciences Inc. | 34 |
11 |
| Autres propriétaires | 978 |